Literature DB >> 8348747

Early induction of IL-1 receptor antagonist (IL-1Ra) in infants and children undergoing surgery.

E M O Nualláin1, P Puri, D J Reen.   

Abstract

The cytokine response to injury or trauma is of interest in terms of both its mediation of the acute phase response and its possible relation to the immunological depression observed after major surgery. In this study, the production of cytokines IL-1 beta, tumour necrosis factor-alpha (TNF-alpha), IL-6 and the naturally occurring inhibitor of IL-1, IL-1Ra, have been investigated in infants and children undergoing Swenson's pull-through operation for Hirschsprung's disease. Samples of peripheral blood were taken before, during and after surgery for the measurement of cytokines. IL-1Ra levels increased significantly (P < 0.01) at 2 h after commencement of surgery, with maximal levels for individual patients being attained between 3 h and 5 h (range 7.6-67.9 ng/ml). The mean level of IL-1Ra was maximal (26.2 ng/ml) at 5 h and returned to baseline levels between 24 h and 72 h. There were no changes observed in the circulating levels of IL-1 beta in nine out of 11 patients following commencement of surgery. TNF-alpha levels did not increase in any of the patients studied. IL-6 levels increased significantly (P < 0.02) 3 h after commencement of surgery, reaching maximum concentrations at 24 h (range 20-670 pg/ml), with levels falling between 48 h and 72 h. This study demonstrates, in vivo, the independent induction of IL-1Ra without a concomitant increase of IL-1 beta levels after major surgery. It also shows that IL-1Ra is the earliest cytokine produced in response to surgical stress.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348747      PMCID: PMC1554828          DOI: 10.1111/j.1365-2249.1993.tb07969.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

Review 1.  Hypothalamo-pituitary responses to trauma.

Authors:  J C Buckingham
Journal:  Br Med Bull       Date:  1985-07       Impact factor: 4.291

2.  Correlation of plasma cytokine elevations with mortality rate in children with sepsis.

Authors:  J S Sullivan; L Kilpatrick; A T Costarino; S C Lee; M C Harris
Journal:  J Pediatr       Date:  1992-04       Impact factor: 4.406

3.  The release of interleukin-1 beta (IL-1) precedes that of interleukin 6 (IL-6) in patients undergoing major surgery.

Authors:  R J Baigrie; P M Lamont; M Dallman; P J Morris
Journal:  Lymphokine Cytokine Res       Date:  1991-08

4.  Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats.

Authors:  H R Alexander; G M Doherty; D J Venzon; M J Merino; D L Fraker; J A Norton
Journal:  Surgery       Date:  1992-08       Impact factor: 3.982

5.  Failure of IL-1 receptor antagonist and monoclonal anti-IL-1 receptor antibody to inhibit antigen-specific immune responses in vivo.

Authors:  D A Faherty; V Claudy; J M Plocinski; K Kaffka; P Kilian; R C Thompson; W R Benjamin
Journal:  J Immunol       Date:  1992-02-01       Impact factor: 5.422

6.  Natural and recombinant interleukin 1 receptor antagonist does not inhibit human T-cell proliferation induced by mitogens, soluble antigens or allogeneic determinants.

Authors:  L P Nicod; F el Habre; J M Dayer
Journal:  Cytokine       Date:  1992-01       Impact factor: 3.861

7.  Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.

Authors:  E Fischer; M A Marano; K J Van Zee; C S Rock; A S Hawes; W A Thompson; L DeForge; J S Kenney; D G Remick; D C Bloedow
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

8.  Inhibition of interleukin-1 (alpha and beta), interleukin-2 secretion and surface expression of interleukin-2 receptor (IL-2R) by a novel cytokine interleukin-1 receptor antagonist (IL-1ra).

Authors:  P Conti; M R Panara; A M Porrini; D Gambi; R C Barbacane; M Reale; M Bongrazio; R A Dempsey
Journal:  Scand J Immunol       Date:  1992-07       Impact factor: 3.487

9.  Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease.

Authors:  E Fischer; K J Van Zee; M A Marano; C S Rock; J S Kenney; D D Poutsiaka; C A Dinarello; S F Lowry; L L Moldawer
Journal:  Blood       Date:  1992-05-01       Impact factor: 22.113

10.  Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis.

Authors:  F Cominelli; C C Nast; A Duchini; M Lee
Journal:  Gastroenterology       Date:  1992-07       Impact factor: 22.682

View more
  5 in total

1.  The soluble tumor necrosis factor receptor I is an early predictor of local infective complications after colorectal surgery.

Authors:  Robert Slotwiński; Waldemar L Olszewski; Andrzej Chaber; Maciej Slodkowski; Marzanna Zaleska; Ireneusz W Krasnodebski
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

2.  Naturally acquired regulatory mechanism of perioperative cytokine response in neonates.

Authors:  M Inoue; C Miki; Y Okita; K Otake; S Yoshiyama; K Uchida; M Kusunoki
Journal:  Pediatr Surg Int       Date:  2006-11-08       Impact factor: 1.827

3.  Decreased monocyte class II MHC expression following major abdominal surgery in children is related to operative stress.

Authors:  M McHoney; N J Klein; S Eaton; A Pierro
Journal:  Pediatr Surg Int       Date:  2006-02-22       Impact factor: 1.827

4.  Pediatric Perioperative Stress Responses and Anesthesia.

Authors:  Koichi Yuki; Erika Matsunami; Kazumasa Tazawa; Wei Wang; James A DiNardo; Sophia Koutsogiannaki
Journal:  Transl Perioper Pain Med       Date:  2017

5.  The multifaceted effects of polysaccharides isolated from Dendrobium huoshanense on immune functions with the induction of interleukin-1 receptor antagonist (IL-1ra) in monocytes.

Authors:  Juway Lin; Ya-Jen Chang; Wen-Bin Yang; Alice L Yu; Chi-Huey Wong
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.